These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 16444031)

  • 1. [Effect of prestarium in patients with chronic heart failure].
    Abashidze TB; Lortkipanidze RM
    Georgian Med News; 2005 Dec; (129):54-7. PubMed ID: 16444031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effects of angiotensin-converting enzyme inhibitors and cosaar on quality of life of patients with pulmonary tuberculosis and chronic heart failure].
    Ditiatkov AE; Tikhonov VA; Radzevich AE
    Probl Tuberk; 2001; (8):37-9. PubMed ID: 11767390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effects of perstarium on the systolic and diastolic functions of the myocardium in patients with chronic cardiac failure].
    Fomina IG; Georgadze ZO; Sinitsyna MG; Gaĭdamakina NE; Nagieva AZ; Matveev VV
    Klin Med (Mosk); 2001; 79(8):20-3. PubMed ID: 11588778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effectiveness of prestarium in the treatment of chronic cor pulmonale].
    Lutaĭ AV; Shutemova EA; Egorova LA; Bogatyreva NV; Khalezova MA; Efimova EG
    Ter Arkh; 2000; 72(9):60-3. PubMed ID: 11076421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The angiotensin-converting enzyme inhibitor perindopril in the treatment of congestive heart failure].
    Tereshchenko SN; Drozdov VN; Demidova IV; Levchuk NN; Moiseev VS
    Ter Arkh; 1997; 69(7):53-6. PubMed ID: 9424761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical and hemodynamical efficacy of prestarium and its role in the treatment of chronic pulmonary heart].
    Korneĭchuk NN; Butorov IV; Verbitskiĭ ON; Butorova VG; Paraska VI
    Ter Arkh; 2003; 75(10):83-7. PubMed ID: 14669615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The perindopril in elderly people with chronic heart failure (PEP-CHF) study.
    Cleland JG; Tendera M; Adamus J; Freemantle N; Polonski L; Taylor J;
    Eur Heart J; 2006 Oct; 27(19):2338-45. PubMed ID: 16963472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of a combination of teveten and prestarium in patients with chronic heart failure].
    Gorgoshidze ML; Abashidze TB
    Georgian Med News; 2005 Jun; (123):18-21. PubMed ID: 16052048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficiency of perstarium in the treatment of patients with chronic obstructive bronchitis and pulmonary hypertension].
    Buturov IV; Buturov SI; Verbitskiĭ ON; Guzun RG; Paraska VI
    Probl Tuberk Bolezn Legk; 2003; (11):26-9. PubMed ID: 14689794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The therapeutic role of RAS blockade in chronic heart failure.
    Werner CM; Böhm M
    Ther Adv Cardiovasc Dis; 2008 Jun; 2(3):167-77. PubMed ID: 19124420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renin angiotensin blockade in heart failure with preserved ejection fraction: The signal gets stronger.
    McMurray J
    Eur Heart J; 2006 Oct; 27(19):2257-9. PubMed ID: 16963471
    [No Abstract]   [Full Text] [Related]  

  • 13. Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure.
    Le Jemtel TH; Padeletti M; Jelic S
    J Am Coll Cardiol; 2007 Jan; 49(2):171-80. PubMed ID: 17222727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term change in distance walked in 6 min is an indicator of outcome in patients with chronic heart failure in clinical practice.
    Passantino A; Lagioia R; Mastropasqua F; Scrutinio D
    J Am Coll Cardiol; 2006 Jul; 48(1):99-105. PubMed ID: 16814655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of the renin-angiotensin-aldosterone system in chronic heart failure: choice of agents and clinical impact.
    Jorde UP
    Cardiol Rev; 2006; 14(2):81-7. PubMed ID: 16493245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease.
    Berger AK; Duval S; Manske C; Vazquez G; Barber C; Miller L; Luepker RV
    Am Heart J; 2007 Jun; 153(6):1064-73. PubMed ID: 17540211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The hemostasis parameters and ACE gene polymorphism in patients with essential hypertension treated with perindopril].
    Janczak-Bazan A
    Ann Acad Med Stetin; 2006; 52(1):51-61; discussion 61-2. PubMed ID: 17131847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
    Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Recent advances and limitations of medical treatment on heart failure].
    Momomura S
    Kyobu Geka; 2007 Jun; 60(6):484-7. PubMed ID: 17564066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of perindopril on long-term clinical outcome of patients with coronary artery disease and preserved left ventricular function.
    Bertrand ME; Remme WJ; Fox KM; Ferrari R; Simoons ML;
    Int J Cardiol; 2007 Sep; 121(1):57-61. PubMed ID: 17270296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.